RNS Number : 8515Q
ValiRx PLC
20 December 2024

20 December 2024

VALIRX PLC

("ValiRx" or the "Company")

ValiRx launches new interactive investor website
providing shareholders with a more proactive way of communication and enquiry support

ValiRx, a life science company focusing on early-stage cancer therapeutics and women's health, is pleased to announce the launch of our interactive investor website.

For both existing and prospective shareholders, the new investor hub brings all ValiRx content into a single integrated platform to better inform and engage with investors and stakeholders, including:

- Regulatory announcements
- Reports
- Presentations
- Educational material
- Interviews
- Corporate research

The investor hub also provides an interactive online experience allowing ValiRx stakeholders to comment on and ask the ValiRx team questions via a portal which will be monitored and responded to in a timely manner.

The Company's AIM Rule 26 website address and all information required by AIM Rule 26 remains unchanged.

How to sign up for the ValiRx investor hub:

1. Visit www.valirx.com
2. Follow the prompts to sign up for an investor hub account
3. Complete your account profile

Mark Eccleston, CEO, commented:

"As a life sciences company focused on advancing cutting-edge therapies, it is essential that we keep our shareholders informed and engaged throughout our journey. InvestorHub enables us to identify and understand our investor base more clearly, allowing us to tailor communications that highlight key milestones, clinical developments, and the value of our progress. This ensures our shareholders remain aligned with our mission to deliver innovative solutions in healthcare."

Ends

Engage with the ValiRx management team directly by asking questions, watching video summaries and seeing what other shareholders have to say. Navigate to our Interactive Investor hub here:https://valirx.com/s/cc8ef3

The Directors are responsible for the release of this announcement.

For further information, please contact:

Investor questions on this announcement We encourage all investors to share questions	https://valirx.com/link/vPn48e

on this announcement via our investor hub	
ValiRx plc Dr Mark Eccleston, CEO	**Tel: +44 (0) 2476 796496** www.valirx.com Mark.Eccleston@valirx.com
Shard Capital Partners LLP (Sole Broker) Damon Heath	**Tel: +44 (0) 20 7186 9000**
V Formation (Public Relations) Lucy Wharton - Senior PR Executive Sue Carr - Director	**+44 (0) 115 787 0206** www.vformation.biz lucy@vformation.biz sue@vformation.biz

Subscribe to our news alert service:https://valirx.com/s/f298d1

This communication is a "Reach" announcement. Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained in this announcement is of a non-regulatory nature. Information required to be notified under the AIM Rules for Companies, Market Abuse Regulation or other regulation would be disseminated as an RNS regulatory announcement and not on RNS Reach.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NRAGPGPWPUPCPWB